The Protocol and Data Management Office (PDMO) of the University of Chicago Cancer Research Center (UCCRC) is a shared resource that provides expertise for protocol and data management of cancer-related research projects. This resource provides cancer center members with broad-based support for their clinical research activities. The services are essential for the collection of high quality data necessary for a successful trial. Since the last submission of the Cancer Center Support Grant, the facility has been reorganized to separate the biostatistical component from the protocol and data management component. The office has been renamed as the Protocol and Data Management Office. Dr. Everett Vokes remains director of this facility. Dr. John Bailar was appointed director of the Biostatistics Facility.
The specific aims of the Protocol and Data Management Office are: 1. To facilitate and coordinate protocol design, development, and implementation; 2. To facilitate review and approval of the protocol by the Institutional Review Board, and the UCCRC Clinical Trials Review Committee (CTRC). To maintain all correspondence with both committees and assure compliance with federal guidelines for investigational drug use and toxicity reporting; 3. To provide for central patient registration, and randomization (when applicable) on all protocols, and to implement effective procedures for receipt and storage of the data collected; 4. To provide quality assurance and timely and accurate interim reporting of the accumulating data as required by the protocol and the sponsoring agencies; 5. To develop, operate and maintain an automated computer database and network communication system that will satisfy the scientific and administrative needs of the facility; 6. To develop and provide central maintenance for the design, content, operations, and security of the study database; 7. To monitor patient accrual and assure timely closure of over- or under-accruing studies with the input of the CTRC and the Biostatistics Facility, and 8. To provide training and education of new personnel in data management requirements, protocol elements and clinical trials monitoring.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-27
Application #
6397816
Study Section
Project Start
2000-08-01
Project End
2002-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
27
Fiscal Year
2000
Total Cost
$289,716
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications